The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.

The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. JACC Cardiovasc Interv. 2016 08 08; 9(15):1576-85.

View in: PubMed

subject areas

Aged
Angina Pectoris
Antigens, CD34
Biomarkers
Double-Blind Method
Early Termination of Clinical Trials
Endothelial Progenitor Cells
Exercise Tolerance
Female
Humans
Male
Middle Aged
Neovascularization, Physiologic
Recovery of Function
Risk Factors
Stem Cell Transplantation
Time Factors
Transplantation, Autologous
Treatment Outcome
United States

authors with profiles

Gary Schaer